(Q43795952)

English

Long-term evaluation of recombinant interferon alpha2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan

scientific article published in November 2001

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Long-term evaluation of recombinant interferon alpha2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in Taiwan (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

chronic hepatitis B

1 reference

based on heuristic

inferred from title

Yi-Hsiang Huang

4

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

author name string

C C Lin

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

J C Wu

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

T T Chang

3

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Y J Wang

5

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

S H Tsay

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

N H Chow

7

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

F Y Chang

8

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

S D Lee

9

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

publication date

1 November 2001

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

438-446

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Long-term follow-up of anti-HBe-positive chronic active hepatitis B.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00320.X

21 January 2018

Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00320.X

21 January 2018

Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00320.X

21 January 2018

A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00320.X

21 January 2018

Vertical Transmission of Hepatitis B Antigen in Taiwan

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00320.X

21 January 2018

Postnatal infectivity of hepatitis B surface antigen-carrier mothers.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00320.X

21 January 2018

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00320.X

21 January 2018

Multiple viral infection as the most common cause of fulminant and subfulminant viral hepatitis in an area endemic for hepatitis B: application and limitations of the polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00320.X

21 January 2018

Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00320.X

21 January 2018

Avoiding false positives with PCR

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00320.X

21 January 2018

Cytotoxic T lymphocyte responses and CTL epitope escape mutation in HBsAg, anti-HBe positive individuals

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00320.X

21 January 2018

Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00320.X

21 January 2018

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00320.X

21 January 2018

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00320.X

21 January 2018

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00320.X

21 January 2018

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00320.X

21 January 2018

Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00320.X

21 January 2018

Response to Interferon-α2a in Patients with e Antigen-Negative Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00320.X

21 January 2018

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00320.X

21 January 2018

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2893.2001.00320.X

21 January 2018

Identifiers

10.1046/J.1365-2893.2001.00320.X

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43795952&oldid=2103407215"